BROOKLYN IMMUNOTHERAPEUTICS (BTX)

Company Profile

Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. The company is headquartered in Brooklyn, New York and currently employs 10 full-time employees. The firm is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The firm also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

Company Info

BROOKLYN IMMUNOTHERAPEUTICS

140 58Th Street, Building A, Suite 2100

Brooklyn NEW YORK 92009

P: 12125821199.0

CEO: Allen Wolff

Employees: 10

Website: https://www.buzztime.com/